This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Pharma Clinical Trial Services: World Market 2013-2023

7. Pharma Clinical Trial Services Market: Industry Trends 2013-2023

7.1 Pharma Clinical Trial Services Market: Strengths and Weaknesses 2012

7.2 Pharma Clinical Trial Services Market: Opportunities and Threats 2013-2023

7.2.1 CRO Expertise in Biosimilars as an Opportunity

7.3 Pharma Clinical Trial Services Market: STEP Analysis 2013-2023

7.4 Social Factors Affecting Clinical Trials 2013-2023

7.4.1 Drug Developers Must Deal with Ethical Considerations to Clinical Trials

7.4.2 Patient Recruitment: The Leading Cause of Trial Delays

7.4.3 Investing to Maintain Patient Enrolment

7.4.3.1 Social Media as a Tool for Engaging Patients in Trials

7.5 Improving Technology for More-Efficient Trials

7.5.1 eClinical Trial Tools

7.5.1.1 Electronic Health Records for Faster Patient Recruitment

7.5.2 Cloud Computing as a Tool for Multicentre Trials

7.5.3 Electronic Data Capture

7.6 Economic Considerations for Clinical Trial Outsourcing

7.6.1 Pharma is Adjusting its R&D Strategies

7.6.2 CROs are Attractive for Private Investors

7.7 Political and Regulatory Developments Affecting Clinical Trials

7.7.1 Drug Safety and Clinical Trials Post-Approval

7.7.2 Cutting Red Tape and Other Regulatory Developments

7.8 Future Growth Strategies for CROs

7.8.1 Strategic Partnering for Long Term Revenue Growth

7.8.1.1 Sharing Risk Between Pharma and CROs

7.8.2 What Strategies Are Used for Selecting a CRO?

7.8.2.1 Small Pharmaceutical Companies and CROs

7.8.3 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

7.8.4 CROs Can Specialise to Grow

7.8.4.1 Orphan Diseases Are an Opportunity for Specialisation

7.9 The Future of Clinical Trials and CROs

7.9.1 New Trial Designs

7.9.1.1 Optimising Clinical Trials for Efficient Drug Development

7.9.2 Clinical Trial Globalisation

7.9.2.1 Consequences of Increased Outsourcing to Emerging Markets

7.9.3 Clinical Trials Have Become Increasingly Complex

7.10 Biomarkers Are Useful Tools for Accelerating Drug Development

8. Leading CROs in the Clinical Trials Services Industry in 2013

8.1 The Pharma Clinical Trial Services Market by Company 2011-20128.2 Quintiles: The Largest Player in the Pharma Clinical Trial Services Market8.2.1 Embracing Technology for New Service Offerings8.2.2 Expanding in Developed and Emerging Markets8.2.3 Will Quintiles Remain the Market Leader to 2023?8.3 Covance Is a Market Leader in Early Phase Services8.3.1 Covance Reorganises its Early Phase Sites8.3.2 Strong Late Phase Revenue Growth 2007-20118.3.3 How Will Covance Extend its Services Beyond 2012?8.4 PPD8.4.1 PPD: Another Global CRO to be Taken Private8.4.2 Investing in Technology for Growth8.4.3 PPD: Outlook 2013-20238.5 Parexel International8.5.1 Parexel is Targeting Growth in Asia8.5.2 Strong Growth for Clinical Trial Services 2010-20128.5.3 New Areas of Specialisation for Parexel8.6 ICON8.6.1 Multiple Acquisitions Have Increased ICON's Service Range8.6.1.1 Expanding Operations in China8.6.2 ICON: Recent Financial Performance and Outlook 2013-20238.7 INC Research8.7.1 From Mid-Sized to Large CRO: INC Acquires Kendle8.7.2 INC Adds New Technological Capabilities8.8 inVentiv Health8.8.1 Three Acquisitions Move inVentiv Closer to the Big Players8.8.2 Clinical Trial Service Revenue Growth 2011 and Beyond8.9 PRA International8.9.1 New Site Openings in Emerging Markets 2011-20128.9.2 Future Directions for PRA International8.10 CMIC: Japan's Largest CRO8.10.1 Increasing Asian Regional Reach8.10.2 CMIC Recent and Future Performance Analysis: An Asian Specialist8.11 Chiltern International8.11.1 Expanding into New Emerging Markets with Offices in Israel andTaiwan8.11.2 Chiltern International: Opportunities for Growth 2013-20238.12 There Are Many Other CROs in the Market in 20128.12.1 Charles River Laboratories Is an Expert in Pre-Clinical Services8.12.2 Clinipace Worldwide Is a Digital CRO8.12.2.1 Rapidly Expanding Through Acquisitions8.12.2.2 Clinipace Offers Many Technology Solutions8.12.3 ReSearch Pharmaceutical Services (RPS)8.12.4 Theorem Clinical Research8.12.4.1 An Established Presence in China8.12.5 WuXi PharmaTech8.12.5.1 WuXi is New to the Clinical Trial Services Market8.13 Leading Company Analysis8.13.1 Emerging Market Entry and Expansion8.13.2 How Are Global CROs Using Technology?8.13.3 How Are Leading Players Seeking to Differentiate Themselves?8.13.4 Medium-Sized Players Growing Larger Through Multiple Acquisitions8.13.5 Large CROs and Strategic Partnerships with Big Pharma

9. Research Interviews

9.1 Jodi Andrews, CEO, ProTrials Research

9.1.1 ProTrials Research

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs